In these trials, various tumor antigen targets, including HER2, EGFRvIII, IL13Ralpha2, CLTX, B7‐H3, IL‐8 receptor, NKG2D, IL7Ra, and CD147 were evaluated for the treatment of glioblastoma with first, second, third, and fourth generation CAR cells employing different integrated therapy approaches. Here, KLRK1 is linked to glioblastoma.